Key result
SGLT2i and GLP-1RA prevent cardiovascular events and stabilize plaques in T2D and impaired glucose tolerance.
Why the study?
Type 2 diabetes mellitus and impaired glucose tolerance significantly induce advanced coronary artery disease and systemic atherosclerosis, raising questions about medical treatments to stabilize plaques and improve clinical outcomes.
Do oral antihyperglycemic drugs improve clinical outcomes and stabilize atherosclerotic plaques in patients with type 2 diabetes mellitus and impaired glucose tolerance?
Do oral antihyperglycemic drugs improve clinical outcomes and stabilize atherosclerotic plaques in patients with type 2 diabetes mellitus and impaired glucose tolerance?
Oral antihyperglycemic agents may play a role in stabilizing atherosclerotic plaques and preventing cardiovascular events in patients with type 2 diabetes and impaired glucose tolerance.
May support CV risk reduction in type 2 diabetes; leaves open causal plaque stabilization pending prospective trials.
Type 2 diabetes mellitus and impaired glucose tolerance (IGT) significantly induce advanced coronary artery disease and systemic atherosclerosis. Thus, type 2 diabetes mellitus and IGT are traditional risk factors of cardiovascular disease. In contrast, acute coronary syndrome is frequently caused by the rupture of coronary atherosclerotic plaques, which reduces patients' quality of life and might result in death. To date, many trials have sought to identify ways to determine the coronary plaque volume and its vulnerability, and many studies have shown that some specific antihyperglycemic agents might prevent coronary or carotid plaque progression, decrease plaque volume, induce plaque stability, and improve clinical outcomes in patients with type 2 diabetes mellitus and IGT. This article reviews the following: (i) the association between coronary or carotid plaques and abnormal glucose tolerance, including type 2 diabetes mellitus; and (ii) the effects of oral antihyperglycemic drugs to improve clinical outcomes and stabilize atherosclerotic plaques in patients with type 2 diabetes mellitus and IGT.
No takes yet. Share an insight, caveat, or question.
Hideki Ishii (2022) conducted a review in Type 2 diabetes mellitus and impaired glucose tolerance. Oral antihyperglycemic drugs was evaluated. Various oral antihyperglycemic agents, such as SGLT2 inhibitors and GLP-1 receptor agonists, demonstrate beneficial effects in preventing cardiovascular events and stabilizing atherosclerotic plaques in patients with type 2 diabetes and impaired glucose tolerance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: